|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000168743 |
Summary for NPNT |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000168743 | Gene symbol | NPNT |
| Gene name | nephronectin | |
| HGNC | 27405 | |
| Entrez ID | 255743 | |
| Gene type | protein_coding | |
| Synonyms | NPNT|EGFL6L|POEM | |
| UniProtAcc | Q6UXI9 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for NPNT |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| NPNT | 1.17e+04 | 1.49e+00 | 4.24e-01 | 3.50e+00 | 4.58e-04 | 6.38e-03 | BRCA |
| Differentially expressed gene analysis between tumor male and normal male samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| NPNT | 3.15e+03 | 3.11e+00 | 6.63e-01 | 4.69e+00 | 2.75e-06 | 1.79e-05 | CHOL |
| Differentially expressed gene analysis between tumor female and normal female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| NPNT | 1.07e+04 | 1.92e+00 | 1.41e-01 | 1.36e+01 | 2.53e-42 | 1.99e-41 | BRCA |
Top |
Sex-biased somatic mutation for NPNT |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for NPNT |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| KIRC | cg05297121 | chr4:105894932 | CGI:chr4:105895258-105896612 | promoter,gene body | 1.95e-01 | 8.33e-02 | 6.15e+00 | 7.90e-10 | 1.01e-08 | 1.12e-01 |
| LIHC | cg05297121 | chr4:105894932 | CGI:chr4:105895258-105896612 | promoter,gene body | 3.03e-01 | 1.57e-01 | 4.26e+00 | 2.04e-05 | 5.09e-05 | 1.46e-01 |
| LIHC | cg23198559 | chr4:105895052 | CGI:chr4:105895258-105896612 | promoter,gene body | 2.47e-01 | 1.31e-01 | 3.13e+00 | 1.73e-03 | 2.57e-03 | 1.16e-01 |
| LIHC | cg03607115 | chr4:105895687 | CGI:chr4:105895258-105896612 | promoter,exon,CDS,gene body | 3.27e-01 | 1.80e-01 | 3.03e+00 | 2.45e-03 | 3.50e-03 | 1.47e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| LIHC | cg26533745 | chr4:105895613 | CGI:chr4:105895258-105896612 | UTR,promoter,exon,gene body | 1.27e-01 | 1.65e-02 | 2.60e+00 | 9.40e-03 | 1.32e-02 | 1.11e-01 |
Top |
Exon skipping events with PSI in TCGA for NPNT |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Landscape of exon skipping events across multiple cancer types. |
 |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| COAD | exon_skip_425487 | 1.13e-02 | 1.37e-01 | -3.98e+00 | 6.79e-05 | 4.20e-04 | -1.26e-01 |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| STAD | exon_skip_425487 | 3.83e-02 | 1.51e-01 | -2.79e+00 | 5.26e-03 | 1.77e-02 | -1.12e-01 |
| READ | exon_skip_425487 | 1.04e-02 | 1.19e-01 | -3.03e+00 | 2.42e-03 | 1.10e-02 | -1.09e-01 |
Top |
RNA A-to-I editing events in TCGA for NPNT |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for NPNT |
| TFs related to NPNT. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| BRCA | BARX2 | NPNT | 4.73e+00 | 9.86e-01 | 3.47e+00 | 9.14e-03 | Male-biased |
| BRCA | DMRT3 | NPNT | 4.89e+00 | 9.89e-01 | 3.52e+00 | 6.85e-03 | Male-biased |
| BRCA | DMRTA1 | NPNT | 4.79e+00 | 9.88e-01 | 3.44e+00 | 6.92e-03 | Male-biased |
| BRCA | DMRTA2 | NPNT | 4.81e+00 | 9.89e-01 | 3.45e+00 | 6.84e-03 | Male-biased |
| BRCA | FOXA1 | NPNT | 4.40e+00 | 9.87e-01 | 2.88e+00 | 4.14e-03 | Male-biased |
| BRCA | FOXD3 | NPNT | 4.45e+00 | 9.89e-01 | 2.82e+00 | 2.97e-03 | Male-biased |
| BRCA | FOXG1 | NPNT | 4.39e+00 | 9.88e-01 | 2.70e+00 | 2.52e-03 | Male-biased |
| BRCA | FOXJ3 | NPNT | 4.10e+00 | 9.81e-01 | 2.64e+00 | 4.79e-03 | Male-biased |
| BRCA | MEF2A | NPNT | 4.18e+00 | 9.84e-01 | 2.54e+00 | 2.92e-03 | Male-biased |
| BRCA | MEF2D | NPNT | 4.31e+00 | 9.81e-01 | 3.03e+00 | 8.28e-03 | Male-biased |
| BRCA | NKX3-1 | NPNT | 4.83e+00 | 9.92e-01 | 3.25e+00 | 3.65e-03 | Male-biased |
| BRCA | SOX9 | NPNT | 4.55e+00 | 9.83e-01 | 3.32e+00 | 9.88e-03 | Male-biased |
| BRCA | ZNF334 | NPNT | 4.51e+00 | 9.92e-01 | 2.35e+00 | 5.94e-04 | Male-biased |
| BRCA | ZNF418 | NPNT | 4.36e+00 | 9.91e-01 | 1.14e+00 | 1.81e-05 | Male-biased |
| BRCA | ZNF79 | NPNT | 4.28e+00 | 9.89e-01 | 2.14e+00 | 6.33e-04 | Male-biased |
| PAAD | BARX2 | NPNT | 4.58e+00 | 9.84e-01 | 3.75e+00 | 1.02e-02 | Male-biased |
| PAAD | DMRT3 | NPNT | 4.58e+00 | 9.84e-01 | 3.76e+00 | 1.03e-02 | Male-biased |
| PAAD | DMRTA1 | NPNT | 4.49e+00 | 9.82e-01 | 3.67e+00 | 1.05e-02 | Male-biased |
| PAAD | DMRTA2 | NPNT | 4.52e+00 | 9.82e-01 | 3.72e+00 | 1.17e-02 | Male-biased |
| PAAD | FOXA1 | NPNT | 4.09e+00 | 9.82e-01 | 3.11e+00 | 4.75e-03 | Male-biased |
| PAAD | FOXD3 | NPNT | 4.13e+00 | 9.84e-01 | 3.14e+00 | 4.27e-03 | Male-biased |
| PAAD | FOXG1 | NPNT | 4.05e+00 | 9.84e-01 | 2.96e+00 | 2.56e-03 | Male-biased |
| PAAD | NANOG | NPNT | 4.34e+00 | 9.86e-01 | 3.39e+00 | 5.54e-03 | Male-biased |
| PAAD | NKX3-1 | NPNT | 4.44e+00 | 9.83e-01 | 3.60e+00 | 9.58e-03 | Male-biased |
| PAAD | PRDM1 | NPNT | 4.06e+00 | 9.82e-01 | 3.08e+00 | 4.56e-03 | Male-biased |
| PAAD | SOX9 | NPNT | 4.45e+00 | 9.84e-01 | 3.58e+00 | 8.46e-03 | Male-biased |
| PAAD | ZNF334 | NPNT | 4.12e+00 | 9.88e-01 | 2.65e+00 | 3.35e-04 | Male-biased |
| PAAD | ZNF79 | NPNT | 3.82e+00 | 9.80e-01 | 2.47e+00 | 6.51e-04 | Male-biased |
| PAAD | ZNF85 | NPNT | 4.13e+00 | 9.82e-01 | 3.18e+00 | 5.60e-03 | Male-biased |
| SKCM | BARHL2 | NPNT | 4.01e+00 | 1.17e-02 | 4.94e+00 | 9.81e-01 | Female-biased |
| SKCM | BARX2 | NPNT | 3.34e+00 | 4.35e-03 | 4.58e+00 | 9.84e-01 | Female-biased |
| SKCM | DMRT3 | NPNT | 3.59e+00 | 6.52e-03 | 4.70e+00 | 9.83e-01 | Female-biased |
| SKCM | DMRTA1 | NPNT | 3.37e+00 | 5.23e-03 | 4.55e+00 | 9.82e-01 | Female-biased |
| SKCM | DMRTA2 | NPNT | 3.51e+00 | 6.24e-03 | 4.64e+00 | 9.83e-01 | Female-biased |
| SKCM | LHX2 | NPNT | 4.00e+00 | 8.48e-03 | 5.04e+00 | 9.85e-01 | Female-biased |
| SKCM | NKX3-1 | NPNT | 3.17e+00 | 2.97e-03 | 4.53e+00 | 9.84e-01 | Female-biased |
| SKCM | PBX4 | NPNT | 3.63e+00 | 8.62e-03 | 4.65e+00 | 9.80e-01 | Female-biased |
| NPNT related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for NPNT |
| RBPs related to ES in NPNT. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| NPNT related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs17025657 | chr4:96575842:G:A | - | 0.55072904960324 | 0.0351530779750262 | GBM | Female-baised eQTL |
| rs113464789 | chr4:106633863:T:A | - | 0.22385079680858 | 0.0346318791981386 | KIRP | Female-baised eQTL |
| rs72679802 | chr4:114882943:A:G | - | 0.191799303510256 | 0.0126950580498919 | LIHC | Female-baised eQTL |
| rs72681403 | chr4:114883043:C:A | - | 0.191799303510256 | 0.0126950580498919 | LIHC | Female-baised eQTL |
| rs72681404 | chr4:114883246:G:T | - | 0.191799303510256 | 0.0126950580498919 | LIHC | Female-baised eQTL |
| rs2019195 | chr4:114860745:A:G | - | 0.169276966119729 | 0.0345313374918389 | LIHC | Female-baised eQTL |
| rs72679768 | chr4:114861693:G:T | - | 0.169276966119729 | 0.0345313374918389 | LIHC | Female-baised eQTL |
| rs72679769 | chr4:114861701:A:G | - | 0.169276966119729 | 0.0345313374918389 | LIHC | Female-baised eQTL |
| rs16997326 | chr4:114861742:A:G | - | 0.169276966119729 | 0.0345313374918389 | LIHC | Female-baised eQTL |
| rs72679781 | chr4:114871659:A:T | - | 0.169276966119729 | 0.0345313374918389 | LIHC | Female-baised eQTL |
| rs72679782 | chr4:114871667:C:T | - | 0.169276966119729 | 0.0345313374918389 | LIHC | Female-baised eQTL |
| rs72681405 | chr4:114885570:C:T | - | 0.169734212747015 | 0.0407751576586078 | LIHC | Female-baised eQTL |
| rs17679144 | chr4:114886653:T:G | - | 0.16961529523254 | 0.0418774127109201 | LIHC | Female-baised eQTL |
| rs75847777 | chr4:99630087:T:C | - | 0.177254116549697 | 0.0307607732639507 | BLCA | Female-baised eQTL |
| rs10013883 | chr4:99535122:C:T | - | 0.124558874964781 | 0.0368691290984088 | BLCA | Female-baised eQTL |
| rs434649 | chr4:107050819:T:C | - | -0.0635077253641059 | 0.0307805878252723 | LUAD | Female-baised eQTL |
| rs393169 | chr4:107041186:A:T | - | -0.0634495887755784 | 0.0343529255619983 | LUAD | Female-baised eQTL |
| rs406805 | chr4:107041196:T:G | - | -0.0634495887755784 | 0.0343529255619983 | LUAD | Female-baised eQTL |
| rs429563 | chr4:107050545:T:C | - | -0.0627778746095626 | 0.0343918579967583 | LUAD | Female-baised eQTL |
| rs370122 | chr4:107045621:A:C | - | -0.063281742473763 | 0.0345044765109694 | LUAD | Female-baised eQTL |
| rs379168 | chr4:107048447:C:A | - | -0.0631461467074373 | 0.0356050014019948 | LUAD | Female-baised eQTL |
| rs443312 | chr4:107048637:C:T | - | -0.0631461467074373 | 0.0356050014019948 | LUAD | Female-baised eQTL |
| rs2704332 | chr4:107037826:G:C | - | -0.0630178381977535 | 0.036477312163111 | LUAD | Female-baised eQTL |
| rs2850413 | chr4:107038187:T:C | - | -0.0630178381977535 | 0.036477312163111 | LUAD | Female-baised eQTL |
| rs2704331 | chr4:107039090:G:C | - | -0.0630178381977535 | 0.036477312163111 | LUAD | Female-baised eQTL |
| rs2704330 | chr4:107039476:A:G | - | -0.0630178381977535 | 0.036477312163111 | LUAD | Female-baised eQTL |
| rs2850415 | chr4:107039555:T:C | - | -0.0630178381977535 | 0.036477312163111 | LUAD | Female-baised eQTL |
| rs2866917 | chr4:107039650:T:C | - | -0.0630178381977535 | 0.036477312163111 | LUAD | Female-baised eQTL |
| rs2903426 | chr4:107039670:G:A | - | -0.0630178381977535 | 0.036477312163111 | LUAD | Female-baised eQTL |
| rs2903425 | chr4:107039671:T:G | - | -0.0630178381977535 | 0.036477312163111 | LUAD | Female-baised eQTL |
| rs1573479 | chr4:107039711:A:G | - | -0.0630178381977535 | 0.036477312163111 | LUAD | Female-baised eQTL |
| rs2850416 | chr4:107040112:C:T | - | -0.0630178381977535 | 0.036477312163111 | LUAD | Female-baised eQTL |
| rs2704328 | chr4:107040119:G:A | - | -0.0630178381977535 | 0.036477312163111 | LUAD | Female-baised eQTL |
| rs2704327 | chr4:107040174:A:C | - | -0.0630178381977535 | 0.036477312163111 | LUAD | Female-baised eQTL |
| rs2850417 | chr4:107040317:T:C | - | -0.0630178381977535 | 0.036477312163111 | LUAD | Female-baised eQTL |
| rs6841122 | chr4:107040558:C:T | - | -0.0630178381977535 | 0.036477312163111 | LUAD | Female-baised eQTL |
| rs383567 | chr4:107040610:A:G | - | -0.0630178381977535 | 0.036477312163111 | LUAD | Female-baised eQTL |
| rs406260 | chr4:107040981:T:A | - | -0.0630178381977535 | 0.036477312163111 | LUAD | Female-baised eQTL |
| rs2850414 | chr4:107038467:A:G | - | -0.0624680691778447 | 0.0390904563124604 | LUAD | Female-baised eQTL |
| rs400701 | chr4:107042480:C:T | - | -0.0625202234529209 | 0.0399799351575579 | LUAD | Female-baised eQTL |
| rs373505 | chr4:107044219:T:A | - | -0.0625202234529209 | 0.0399799351575579 | LUAD | Female-baised eQTL |
| rs2704333 | chr4:107037366:T:G | - | -0.0633603731223404 | 0.0406052066788088 | LUAD | Female-baised eQTL |
| rs377783 | chr4:107046799:G:T | - | -0.0629923024174401 | 0.0433581045840972 | LUAD | Female-baised eQTL |
| rs378587 | chr4:107047064:G:T | - | -0.0629923024174401 | 0.0433581045840972 | LUAD | Female-baised eQTL |
| rs416166 | chr4:107055698:A:C | - | -0.0611591474733977 | 0.0444830870086745 | LUAD | Female-baised eQTL |
| rs367473 | chr4:107051297:T:A | - | -0.0604083683268898 | 0.0457613446860204 | LUAD | Female-baised eQTL |
| rs375838 | chr4:107052852:G:A | - | -0.0606105432138132 | 0.0474343574638034 | LUAD | Female-baised eQTL |
| rs402455 | chr4:107052856:T:C | - | -0.0606105432138132 | 0.0474343574638034 | LUAD | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs77288922 | chr4:112830408:A:T | - | 0.358694630887892 | 0.000226694500063003 | SARC | Male-baised eQTL |
| rs78334545 | chr4:112830615:A:T | - | 0.358694630887892 | 0.000226694500063003 | SARC | Male-baised eQTL |
| rs511049 | chr4:110906979:T:C | - | -0.104863062912922 | 0.0351300954765743 | SARC | Male-baised eQTL |
| rs551286 | chr4:110911433:T:A | - | -0.104507834449205 | 0.0372370409095138 | SARC | Male-baised eQTL |
| rs570557 | chr4:110911612:C:T | - | -0.104507834449205 | 0.0372370409095138 | SARC | Male-baised eQTL |
| rs523697 | chr4:110912160:A:G | - | -0.104507834449205 | 0.0372370409095138 | SARC | Male-baised eQTL |
| rs581241 | chr4:110915676:T:C | - | -0.104507834449205 | 0.0372370409095138 | SARC | Male-baised eQTL |
| rs580562 | chr4:110910517:A:G | - | -0.104128153987382 | 0.0397621182645113 | SARC | Male-baised eQTL |
| rs10516589 | chr4:112823084:A:G | - | 0.195945551527342 | 0.045345132129949 | SARC | Male-baised eQTL |
| rs7670379 | chr4:101645554:A:T | - | 0.0768695399310504 | 0.0158227713430852 | LUSC | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000168743 |
| CpG Site: cg22738800 | |
| Position to Gene: gene | |
| Male Effect: - | |
| Female Effect: -0.458020798073433 | |
 | Gene ID: ENSG00000168743 |
| CpG Site: cg22738800 | |
| Position to Gene: gene | |
| Male Effect: -0.453895282368038 | |
| Female Effect: - | |
 | Gene ID: ENSG00000168743 |
| CpG Site: cg22738800 | |
| Position to Gene: gene | |
| Male Effect: -0.455444735856498 | |
| Female Effect: - |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg22738800 | chr4:105900550 | gene | -0.453895282368038 | 2.09728813757499e-11 | -0.4841310808446046 | 1.66505293127131e-14 | LUAD |
| cg22738800 | chr4:105900550 | gene | -0.455444735856498 | 8.7801521375774e-11 | -0.46228550067826646 | 6.894448251983252e-13 | STAD |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg22738800 | chr4:105900550 | gene | -0.458020798073433 | 6.48277602252939e-21 | -0.8637821493918284 | 6.263336890876871e-25 | PAAD |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of NPNT |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
